SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Injective taken over by the community.

Nonja

Nonja is trending as community members highlight its strong performance within the Injective ecosystem and discuss its potential for significant gains, particularly with upcoming Injective upgrades and ETF possibilities. Community members emphasize Nonja's strong community, high burned liquidity, and successful NFT collections, positioning it as a leading meme coin on the Injective blockchain. Discussions also focus on its potential for high returns and its solid chart as positive factors.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending as traders explore privacy-focused cryptocurrencies, drawing comparisons to early Bitcoin due to its limited supply. The community is closely watching Cypherpunk Technologies' (CYPH) accumulation of ZEC, backed by the Winklevoss twins, and speculating on its potential impact. Discussions also highlight ZEC's role in scaling privacy at Layer-2 via Starknet.

this coin is scarce

SCARCE CRYPTO is trending as traders discuss its potential for a breakout, citing a tightening chart and accumulation by larger holders. The community emphasizes its low supply and is watching closely for a significant move, with some comparing it to other Solana-based tokens.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is gaining traction as the community rallies behind its vision within the Bitcoin ecosystem, particularly its role in the Rune revolution. Discussions highlight its potential to drive a Bitcoin-native culture and its commitment to a fair, community-driven approach, with some anticipating upcoming catalysts like ZAP integration.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Strike Coin

Starknet ($STRK) is trending amid discussions about its potential to scale Bitcoin and Ethereum using ZK-STARK technology, with some community members drawing comparisons to Zcash ($ZEC) due to its privacy features. The launch of BTCFi season with significant $STRK incentives has further fueled interest, alongside protocol upgrades and increased developer activity. Some users are also pointing out that the ticker is labeled as Strike Coin, while it is actually Starknet.

Royal Bank of Canada engages in the provision of banking and financial services. It operates through the following segments: Personal and Commercial Banking, Wealth Management, Insurance, Capital Markets, and Corporate Support. The Personal and Commercial Banking segment deals with a broad suite of financial products and services in both individual and business clients in Canada, the Caribbean, and the U.S. The Wealth Management segment offers a suite of wealth, investment, trust, banking, credit, and other advice-based solutions. It also offers other wealth management solutions to institutional and individual clients through its distribution channels and third-party distributors. The Insurance segment refers to a suite of advice and solutions for individual and business clients including life, health, wealth, property and casualty, travel, group benefits, annuities, and reinsurance. The Capital Markets segment is involved in the provision of advisory and origination, sales and trading, lending and financing and transaction banking to corporations, institutional clients, asset managers, private equity firms and governments globally. The Corporate Support segment consists of technology and operations services. The company was founded by J. W. Merkell, Edward Kenny, T. C. Kinnear, James B. Duffus, William Cunard, John Tobin, George P. Mitchell and Jeremiah Northup in 1864 and is headquartered in Toronto, Canada.

Royal Bank Of Canada

Royal Bank of Canada ($RY) is garnering attention due to Elliott Wave analysis suggesting a potential rally continuation before a larger pullback, with some analysts eyeing specific upside targets. Community discussions revolve around identifying the peak of this bullish wave and preparing for a subsequent corrective phase. Recent data indicates resilient consumer spending and stabilization in the housing market, further influencing investor sentiment.

KraneShares Trust - KraneShares CSI China Internet ETF

KraneShares CSI China Internet ETF

KWEB is trending as traders discuss potential breakouts and a possible rotation into Chinese equities, highlighting the ETF's attractive valuations relative to the U.S. market. Recent discussions center on China's economic data, trade relations, and potential government actions impacting the sector. The community is closely watching technical patterns and awaiting catalysts that could drive KWEB higher.

Veeva Systems, Inc. engages in the provision of industry cloud solutions for the global life sciences industry. Its solutions enable pharmaceutical and other life sciences companies to realize the benefits of modern cloud-based architectures and mobile applications for their most critical business functions, without compromising industry-specific functionality or regulatory compliance. The firm's customer relationship management solutions enable its customers to increase the productivity and compliance of their sales and marketing functions. Its regulated content management and collaboration solutions enable its customers to more efficiently manage regulated, content-centric processes across the enterprise. The company's customer master solution enables customers to more effectively manage complex healthcare provider and healthcare organization data. The company was founded by Mark Armenante, Peter P. Gassner, Doug Ostler, Mitch Wallace and Matthew J. Wallach on January 12, 2007, and is headquartered in Pleasanton, CA.

Veeva Systems Inc - Ordinary Shares - Class A

VEEV is trending amid analyst upgrades and discussions around its AI strategy and partnerships, including one with Amazon Web Services. Community discussions highlight its strong Q2 results and potential long-term growth in the life sciences sector, even with rising costs. Technical analysis suggests a mixed market context with some eyeing breakout potential.

Telcoin is a multi-national fintech company  integrating blockchain technology, telecommunications, and digital banking to revolutionize global finance. It aims to provide borderless, instant, and affordable financial services to mobile phone users worldwide. Telcoin offers the Telcoin Wallet, a multi-signature DeFi wallet supporting more than 100 digital assets and remittances to eWallets and bank accounts globally. Telcoin is regulated as a Virtual Asset Service Provider in the EU (Lithuania) and Argentina, a Major Payment Institution in Singapore, and a Money Services Business in the US, Canada, and Australia.   Telcoin is designed to complement telecom, mobile money, and e-wallet partners globally with both traditional fiat and blockchain transaction rails that underpin our fast and affordable digital financial service offerings. Telcoin combines the best parts of the burgeoning DeFi ecosystem with our compliance-focused approach to each market, ensuring that the company takes on a fraction of traditional financial counterparty, execution, and custody risks.  The Telcoin Association is a Swiss non-profit organization domiciled in Lugano, Switzerland and is governed by a decentralized group of Miner Councils that run the various aspects of the Telcoin Platform, including the management of the Telcoin (TEL) token. Read more about the Telcoin Association [here](https://www.telcoin.org).

Telcoin

Telcoin is trending as the community discusses its potential as a top 100 crypto and eventual listing on major exchanges like Coinbase. Excitement is building around Telcoin's final charter approval to launch a digital asset bank, positioning it as a leader in bridging traditional finance with DeFi. Many community members are focused on accumulating $TEL, anticipating significant gains upon broader adoption and exchange listings.

NEOS ETF Trust - NEOS Nasdaq 100 High Income ETF

NEOS Nasdaq 100 High Income ETF

QQQI is trending as traders evaluate its high dividend yield and covered call strategy, with some expressing concerns about potential risks compared to similar ETFs. The community is actively discussing the ETF's tax efficiency and income potential, especially in light of market volatility. Several investors are weighing QQQI against alternatives like JEPQ and SPYI for their income portfolios.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tectonic Therapeutic (NASDAQ:TECX) Issues Earnings Results, Beats Estimates By $0.03 EPS

Tectonic Therapeutic (NASDAQ:TECX - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($1.02) EPS for the quarter, beating analysts' consensus estimates of...

<ul class="summary-bullets"><li>TX45, Tectonic’s experimental Fc-relaxin fusion protein, showed strong improvements in heart and lung function with no serious safety issues in patients with heart failure-related pulmonary hypertension.</li><li>The results expand the drug’s potential reach to a broader patient population with no approved therapies, while the Phase 2 APEX trial continues toward results in 2026.</li><li>Retail investors reacted enthusiastically on Stocktwits, calling the data “unbelievable” and “outstanding.”&nbsp;</li></ul>Shares of Tectonic Therapeutic rose about 30% in after-hours trading on Wednesday after the company reported positive topline results from a Phase 1b Part B clinical trial of TX45, its experimental Fc-relaxin fusion protein, in patients with Group 2 pulmonary hypertension associated with heart failure with reduced ejection fraction.<h2 class="st-heading-2">TX45 Shows Improvements In Heart And Lung Function</h2>Tectonic said a single intravenous dose of TX45 was well tolerated, with no serious side effects or meaningful changes in blood pressure. The treatment showed clear benefits for heart and lung function by reducing pressure on the heart and lungs and improving blood flow. Key measures, such as pulmonary capillary wedge pressure, total pulmonary resistance, and mean pulmonary artery pressure, all decreased, while cardiac output increased.CEO Alise Reicin said the findings “open up the potential to expand into this additional patient population with significant unmet need and no approved therapies,” adding that the results mirrored those seen in an earlier TX45 study in heart failure with preserved ejection fraction.<h2 class="st-heading-2">Broader Development Plan</h2>The trial enrolled 14 patients and builds on earlier positive data from TX45’s Phase 1b Part A study in ejection fraction. The company is currently running the APEX Phase 2 trial to test TX45 over a 24-week treatment period in patients with ejection fraction, with topline results expected in 2026.Chief Medical Officer Marcella Ruddy said the drug showed “persistent effects at day 29” based on echocardiographic data and continued to demonstrate a favorable safety profile.<h2 class="st-heading-2">Stocktwits Users Cheer Tectonic’s TX45 Results</h2>On Stocktwits, retail sentiment for Tectonic Therapeutic was ‘extremely bullish’ amid ‘extremely high’ message volume.One user described the TX45 results as “unbelievable,” predicting the stock could reach $50.&nbsp;<stembedurl>https://stocktwits.com/paddypablo/message/634229088</stembedurl>Another user said the data looked “outstanding,” adding to their position below $22 and expecting the shares to climb further.<stembedurl>https://stocktwits.com/Gurujoe/message/634224719</stembedurl><a href="https://stocktwits.com/symbol/TECX">Tectonic’s stock</a> has declined 60% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tectonic’s stock (TECX) has declined 60% so far in 2025. (Photo credit: Getty Images)

Why Tectonic Therapeutic Stock Soared 30% After-Hours Today

TX45, Tectonic’s experimental Fc-relaxin fusion protein, showed strong improvements in heart and lung function with no serious safety issues in patients with heart failure-related pulmonary hypertension.

Equity

Shares of Tectonic Therapeutic (TECX) soared about 6% in Wednesday’s pre-market after Oppenheimer initiated coverage of the company with an ‘Outperform’ rating.Oppenheimer has an $80 price target on Tectonic, representing an upside of over 380% from the stock’s closing price on Tuesday. The firm stated that it likes the prospects of Tectonic's lead asset, TX45, for addressing prevalent and progressive cardiovascular disorders that are currently inadequately treated.The analyst is optimistic ahead of next year's mid-stage study data readout in pulmonary hypertension with heart failure with preserved ejection fraction, which it believes could pave the way for a multi-billion-dollar global sales opportunity, according to TheFly.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TECX">Tectonic</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:577/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_03_at_7_02_32_AM_png_aa449b866b.webp" alt="TECX's Sentiment Meter and Message Volume as of 7:02 a.m. ET on Sept. 3, 2025 | Source: Stocktwits" width="577" height="62"><figcaption>TECX's Sentiment Meter and Message Volume as of 7:02 a.m. ET on Sept. 3, 2025 | Source: Stocktwits</figcaption></figure>Tectonic shares closed down 35% on Tuesday following Eli Lilly's (LLY) data presentation and publication from its failed study in heart failure patients with preserved ejection fraction using a recombinant long-acting relaxin mimetic, Volenrelaxin. Tectonic’s lead candidate also seeks to treat similar cardiovascular disorders.According to Truist analyst Danielle Brill, the negative news "represents another hit to the emerging relaxin class of drugs." Still, the firm also notes that read-through should be limited as the population enrolled in Lilly's trial is distinct from those enrolled in Tectonic's.The firm, which believes Tectonic's approach to targeting Combined Post- and Pre-Capillary Pulmonary Hypertension has "the strongest rationale" and calls the selloff "overdone," maintained a ‘Buy’ rating and a $64 price target on Tectonic shares.TECX stock is down by 64% this year and by about 13% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/cybersecurity-vendor-zscaler-s-stock-rises-premarket-what-s-fueling-upside/chwTMR0Rd89">Cybersecurity Vendor Zscaler’s Stock Rises Premarket: What’s Fueling The Upside?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Tectonic Stock Soars Pre-market After Tuesday’s Sell-Off: Oppenheimer Is Hopeful About Company’s Lead Candidate

Oppenheimer stated that it likes the prospects of Tectonic's lead asset, TX45, to address prevalent and progressive cardiovascular disorders that are inadequately treated.

Raymond James bullish on biotech firms on favorable valuation

Investing.com -- Raymond James started coverage on biotechnology companies, rating Avidity Biosciences and Disc Medicine at Strong Buy and assigning Outperform ratings to Dyne Therapeutics, Tectonic Therapeutic, and Wave Life Sciences (NASDAQ:WVE), pointing to a sector-wide opportunity amid “suppressed valuations.”

Wall Street Analysts See a 258.52% Upside in Tectonic Therapeutic, Inc. (TECX): Can the Stock Really Move This High?

Buy Rating Affirmed on Tectonic Therapeutics' TX45 for Promising Clinical Advancements

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on TECX stock, giving a Buy rating on July 30. Tyler Van Buren has given his B...

Tectonic Therapeutic Announces COO Departure and Severance Terms

Tectonic Therapeutic (TECX) has shared an announcement. Tectonic Therapeutic, Inc. has reached a separation agreement with its COO, Dr. Christian C...

Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). It develops a proprietary technology platform called GEODe to enable the discovery and development of GPCR-targeted biologic medicines. The company was founded by Timothy A. Springer and Andrew Kruse in November 2015 and is headquartered in Watertown, MA.

Tectonic Therapeutic Inc.

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

TECX
Tectonic Therapeutic Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TECX News

TECXTectonic Therapeutic Inc.